| Name |
|---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
Cardiff Oncology Inc is a clinical-stage biotechnology company advancing cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Its main asset, onvansertib, is a specific, oral PLK1 inhibitor...
Benzinga Rankings give you vital metrics on any stock – anytime.
You can purchase shares of Cardiff Oncology (NASDAQ:CRDF) through any online brokerage.
Other companies in Cardiff Oncology’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Moderna Inc (NASDAQ:MRNA).
Cardiff Oncology has a consensus price target of $8.93.
The stock price for Cardiff Oncology (NASDAQ: CRDF) is $0.9341 last updated October 15, 2026 at 7:01 AM EDT.
There are no upcoming dividends for Cardiff Oncology.
Cardiff Oncology does not have any upcoming earnings scheduled.
There is no upcoming split for Cardiff Oncology.
Cardiff Oncology is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
